Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
rupert.mcshane@oxfordhealth.nhs.uk

Telephone
+44 (0)1865 901000

Websites

Ketamine & Related Compounds for Psychiatric Disorders
The Ketamine International Journal Club runs on second and fourth Tuesdays at 5.30pm GMT. Details of the Ketamine2021 conference, which will run March 25th and 26th 2-6pm online are also posted here.

Rupert McShane

MD FRCPsych

Associate Professor

Consultant Psychiatrist

I am interested in treatment-resistant depression and dementia. Clinically, I lead the Oxfordshire ECT and ketamine services and run a memory clinic. My main focus is developing policy and monitoring arrangements for rapidly acting antidepressants such as ketamine. I lead an international online journal club and chair the steering committee of an international academic conference on Ketamine and Related Compounds for Psychiatric Disorders. I work on ways of optimizing the effects of ketamine and am national CI and local PI for trials of rapidly acting antidepressants. Following an NIHR-funded case series exploring the use of repeated ketamine for resistant depression, we have now treated over 300 patients and are continuing to refine treatment protocols. I chair the Royal College of Psychiatrists Committee on ECT and related treatments. I led a qualitative study of ECT, which led to the creation of a Healthtalk module of patients talking about their experience and an exploration of why experiences are so polarised. When I was Coordinating Editor of the Cochrane Dementia and Cognitive Improvement Group, I led programmes on reviews of diagnostic test accuracy, and modifiable risk factors for dementia. I support NIHR funded and commercial dementia and antidepressant trials as local PI.

Recent publications

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

Knapp M. et al, (2017), Int J Geriatr Psychiatry, 32, 1205 - 1216

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

Singh I. et al, (2017), Lancet Psychiatry, 4, 419 - 426

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings.

Harrison JK. et al, (2016), Cochrane Database Syst Rev, 11

Ketamine: stimulating antidepressant treatment?

Malhi GS. et al, (2016), BJPsych Open, 2, e5 - e9

Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial.

Atherton N. et al, (2016), Trials, 17

Ketamine and other glutamate receptor modulators for depression in adults

Caddy C. et al, (2016), BJ Psych Advances, 22, 214 - 215

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

McCloud TL. et al, (2016), BJ Psych Advances, 22

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

Howard R. et al, (2015), Lancet Neurol, 14, 1171 - 1181

Pharmacological interventions for cognitive decline in people with Down syndrome.

Livingstone N. et al, (2015), Cochrane Database Syst Rev, 2015

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.

McCloud TL. et al, (2015), Cochrane Database Syst Rev

Ketamine and other glutamate receptor modulators for depression in adults.

Caddy C. et al, (2015), Cochrane Database Syst Rev

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

Rendell JM. et al, (2015), Cochrane Database of Systematic Reviews, 2015

Ketamine and other glutamate receptor modulators for depression in adults

Amit BH. et al, (2015), Cochrane Database of Systematic Reviews, 2015

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting.

Harrison JK. et al, (2015), Cochrane Database Syst Rev

Pharmacological interventions for cognitive decline in people with Down syndrome

Livingstone N. et al, (2015), Cochrane Database of Systematic Reviews, 2015

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings

Lees RA. et al, (2014), Cochrane Database of Systematic Reviews, 2014

(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Zhang S. et al, (2014), Cochrane Database Syst Rev, 2014

Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.

Noel-Storr AH. et al, (2014), Neurology, 83, 364 - 373

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting.

Harrison JK. et al, (2014), Cochrane Database Syst Rev

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C. et al, (2014), Cochrane Database Syst Rev, 2014

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

Diamond PR. et al, (2014), J Psychopharmacol, 28, 536 - 544

D-8 for diagnosis of dementia across a variety of healthcare settings

Hendry K. et al, (2014), Cochrane Database of Systematic Reviews, 2014

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations.

Quinn TJ. et al, (2014), Cochrane Database Syst Rev

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL. et al, (2014), Cochrane Database Syst Rev, 2014

Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial.

Leroi I. et al, (2013), Trials, 14

Should patients with dementia who wander be electronically tagged? Yes.

McShane R., (2013), BMJ, 346

Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia.

Noel-Storr AH. et al, (2013), Alzheimers Dement, 9, e96 - e105

Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies.

Davis DH. et al, (2013), Cochrane Database Syst Rev

Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia

Noel-Storr AH. et al, (2013), Alzheimer's and Dementia, 9

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL. et al, (2012), Cochrane Database Syst Rev, 5

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M. et al, (2012), Cochrane Database Syst Rev, 2012

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Howard R. et al, (2012), N Engl J Med, 366, 893 - 903

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.

Farrimond LE. et al, (2012), BMJ Open, 2

systematic review of the quality and reporting standards of longitudinal biomarker studies in dementia

Flicker L. et al, (2012), AUSTRALASIAN JOURNAL ON AGEING, 31, 18 - 18

Harmonisation of reporting for studies of diagnostic accuracy in dementia

Flicker L. et al, (2012), AUSTRALASIAN JOURNAL ON AGEING, 31, 19 - 19

What is this thing called agitation?

McShane R., (2011), BMJ, 343

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Schneider LS. et al, (2011), Archives of Neurology, 68, 991 - 998

PAIN AND AGITATION IN DEMENTIA What is this thing called agitation?

McShane R., (2011), BMJ-BRITISH MEDICAL JOURNAL, 343

MAGD Trial-Memantine for Agitation in Alzheimer's Dementia

Fox C. et al, (2011), JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 59, S65 - S66

REDKITE: KETAMINE AS A TREATMENT FOR DEPRESSION

Atkinson S. and McShane R., (2011), JOURNAL OF PSYCHOPHARMACOLOGY, 25, A17 - A17

REDKITE: KETAMINE AS A TREATMENT FOR DEPRESSION

Atkinson S. and McShane R., (2011), JOURNAL OF PSYCHOPHARMACOLOGY, 25, A17 - A17

PAIN AND AGITATION IN DEMENTIA What is this thing called agitation?

McShane R., (2011), BMJ-BRITISH MEDICAL JOURNAL, 343

Effect of an educational video on the accuracy of surrogate decisions: the case of electroconvulsive therapy.

Pieroni S. and McShane R., (2010), J ECT, 26, 208 - 212

Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges.

Mason SE. et al, (2010), Int J Alzheimers Dis, 2010

Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease.

Gustavsson A. et al, (2010), Int J Geriatr Psychiatry, 25, 622 - 632

Electronic tracking for people with dementia who get lost outside the home: A study of the experience of familial carers

White EB. et al, (2010), British Journal of Occupational Therapy, 73, 152 - 159

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.

Gustavsson A. et al, (2009), Int J Geriatr Psychiatry, 24, 1072 - 1078

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Jones R. et al, (2009), Trials, 10

Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease.

Williams SS. et al, (2009), J Neurol Neurosurg Psychiatry, 80, 667 - 670

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Ballard C. et al, (2009), Lancet Neurol, 8, 151 - 157

andomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).

Ballard C. et al, (2008), PLoS Med, 5

nosmia in subjects with dementia is associated with Lewy pathology in the olfactory pathways

Hubbard PS. et al, (2008), JOURNAL OF ANATOMY, 213, 346 - 346

Memantine for moderate and severe Alzheimer's disease: systematic review and meta-analysis

Minakaran N. et al, (2008), EUROPEAN JOURNAL OF NEUROLOGY, 15, 34 - 34

lpha-synuclein pathology in the olfactory pathways of dementia patients.

Hubbard PS. et al, (2007), J Anat, 211, 117 - 124

Non-pharmacological interventions for wandering of people with dementia in the domestic setting

Hermans DG. et al, (2007), Cochrane Database of Systematic Reviews

Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice.

Van Der Putt R. et al, (2006), Int J Geriatr Psychiatry, 21, 755 - 760

Memantine for dementia.

McShane R. et al, (2006), Cochrane Database Syst Rev

Clioquinol for the treatment of Alzheimer's Disease.

Jenagaratnam L. and McShane R., (2006), Cochrane Database Syst Rev

Memantine for dementia. A Cochrane meta-analysis

Sastre AA. et al, (2005), International Psychogeriatrics, 17, 316 - 317

The Cochrane Collaboration and the work of the Cochrane Dementia and Cognitive Improvement Group (CDCIG)

Hermans D. et al, (2005), International Psychogeriatrics, 17, 318 - 318

The Cochrane Dementia Group's register of trials: a unique resource for dementia specialists

Hermans D. et al, (2005), International Psychogeriatrics, 17, 304 - 304

Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review.

McShane R. and Schneider LS., (2005), Alzheimers Dement, 1, 67 - 71

Olfactory testing and medial temporal lobe width in the early diagnosis of Alzheimer's disease(AD), Mild Cognitive Impairment(MCI) and Dementia with Lewy Bodies(DLB)

Williams S. et al, (2005), INTERNATIONAL PSYCHOGERIATRICS, 17, 266 - 267

Discussant

McShane R., (2005), INTERNATIONAL PSYCHOGERIATRICS, 17, 57 - 57

Memantine for dementia: are we missing something?

McShane R., (2005), INTERNATIONAL PSYCHOGERIATRICS, 17, 38 - 39

Memantine plus donepezil improves physical and mental health in people with Alzheimer's disease.

McShane RH., (2004), Evid Based Ment Health, 7

3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

Ballard CG. et al, (2004), J Clin Psychiatry, 65, 114 - 119

Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease.

Nagy Z. et al, (2002), Neurosci Lett, 317, 81 - 84

Wandering in dementia: a longitudinal study.

Hope T. et al, (2001), Int Psychogeriatr, 13, 137 - 147

nosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology.

McShane RH. et al, (2001), J Neurol Neurosurg Psychiatry, 70, 739 - 743

Calming influence or chemical cosh?

McShane R., (2000), Nurs Times, 96, 28 - 29

What are the syndromes of behavioral and psychological symptoms of dementia?

McShane R., (2000), INTERNATIONAL PSYCHOGERIATRICS, 12, 147 - 153

Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study.

Hope T. et al, (1999), Br J Psychiatry, 174, 39 - 44

Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities.

McShane R. et al, (1998), Psychol Med, 28, 1119 - 1127

Getting lost in dementia: a longitudinal study of a behavioral symptom.

McShane R. et al, (1998), Int Psychogeriatr, 10, 253 - 260

The feasibility of electronic tracking devices in dementia: a telephone survey and case series.

McShane R. et al, (1998), Int J Geriatr Psychiatry, 13, 556 - 563

Behaviour changes in dementia. 2: Are there behavioural syndromes?

Hope T. et al, (1997), Int J Geriatr Psychiatry, 12, 1074 - 1078

Issues in drug treatment for Alzheimer's disease.

McShane R. et al, (1997), Lancet, 350, 886 - 887

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

McShane R. et al, (1997), BMJ, 314, 266 - 270

Do neuroleptic drugs hasten cognitive decline in dementia? Reply

McShane R. et al, (1997), BRITISH MEDICAL JOURNAL, 314, 1412 - 1412

Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search.

Coull JT. et al, (1995), Psychopharmacology (Berl), 121, 222 - 230

Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease.

McShane R. et al, (1995), J Neurol Neurosurg Psychiatry, 59, 185 - 188

Tracking patients who wander: ethics and technology.

McShane R. et al, (1994), Lancet, 343

Tryptophan depletion in normal volunteers produces selective impairments in learning and memory.

Park SB. et al, (1994), Neuropharmacology, 33, 575 - 588

Buspirone-induced hypothermia in normal male volunteers.

Young AH. et al, (1993), Biol Psychiatry, 34, 665 - 666

EDITING MEDICAL RECORDS

MCSHANE R. and ROWE D., (1991), BRITISH MEDICAL JOURNAL, 303, 787 - 787

More publications